
CLAIMS






What is claimed:

1. A compound represented by the formula



or a pharmaceutically acceptable salt thereof, wherein:

A is selected from the group consisting of:





and

;

W is methyl;

G is $-C(O)NH_2$

R_3 is hydroxy;

R_4 is trifluoromethyl or cyclopropyl;

R_{11} at each occurrence is independently hydrogen,

optionally substituted $–C_1$-C_8-alkyl or C_3-C_6-cycloalkyl;

R_{12} at each occurrence is independently selected from the group consisting of:

1) hydrogen;
2) optionally substituted $–C_1$-C_8-alkyl;
3) optionally substituted $–C_3$-C_8-cycloalkyl;
4) optionally substituted 3- to 8-membered heterocyclic;
5) optionally substituted aryl;
6) optionally substituted arylalkyl;
7) optionally substituted heteroaryl; and
8) optionally substituted heteroarylalkyl;

each R_{21} is independently selected from the group consisting of -F, -Cl, -CN, CH_3, $-CF_3$, $-CH_2F$ and $-CHF_2$;

each R_{31} is independently halo; -CN; $-NO_2$, $-OR_{11}$; $-NR_{11}R_{12}$; $-NR_{11}C(O)R_{12}$; $-NR_{11}S(O)_2R_{12}$; $-S(O)_2R_{12}$; $-S(O)_2NR_{11}R_{12}$, $-NR_{11}C(O)NR_{11}R_{12}$; $-C(O)R_{11}$, $-C(O)OR_{11}$; $-C(O)NR_{11}R_{12}$; substituted or unsubstituted $–C_1$-C_6 alkyl; substituted or unsubstituted $–C_3$-C_8-cycloalkyl; substituted or unsubstituted 3- to 8-membered heterocyclic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;


R_{22} is hydrogen, halogen, $-OR_{11}$; $-NR_{11}R_{12}$, substituted or unsubstituted $–C_1$-C_6-alkyl; substituted or unsubstituted $–C_3$-C_8-cycloalkyl; substituted or unsubstituted 3- to 8-membered heterocyclic; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl;

m' is 0 or 1; and

m is 0, 1, or 2;



wherein the term "substituted" refers to substitution by independent replacement of one, two, or three of the hydrogen atoms with substituents selected from halogen, C_1-C_4-alkyl, halo-C_1-C_4-alkyl, C_2-C_4-alkenyl; halo-C_2-C_4-alkenyl; C_3-C_6-cycloalkyl, C_1-C_4-alkoxy, halo-C_1-C_4-alkoxy, -CN, -OH, NH_2, C_1-C_4-alkylamino, di(C_1-C_4-alkyl)amino, and NO_2.















2. The compound of claim 1, wherein E selected from the groups set forth below:






























.















3. The compound of claim 1, selected from the compounds set forth below, or a pharmaceutically acceptable salt thereof:












Compound	Structure	Compound	Structure
28		59	













61		63	
64		79	
80		82	
83		84	
85		86	
87		219	
220		221	












222		223	
224		225	
226		227	
228		240	
241			
245		249	
251		252	













253		254	
255		256	
257		258	
260		261	
262		263	
265		269	
270		272	















273		274	
275		277	
278		279	
280		281	
282		285	
286		287	
312		314	

















		333	
334		336	
337		338	
339		340	
341		342	
343		344	

















345		346	
347		348	
349		350	
351		352	
353		354	
356		360	















363			
385		386	
387		388	
389		392	
393		394	
395		396	















397		398	
399		400	
401		402	
403		404	
405		406	
407		408	













409		410	
411		412	
413		414	
415		416	
417		418	
424		425	
426		427	















428		429	
430		431	
432		433	
434		436	
438		439	
440		441	
442		443	
444		445	












446		447	
448		518	
519		520	
521		522	
523		524	
525		526	
527		528	
529		530	

531		532	
533		534	
535		536	
537		538	
539		540	
541		542	
543		544	

545		546	
547		548	
549		550	
551		552	
553		554	
557		558	
559		560	

561		562	
563		584	
600		611	
613		614	
615		618	
620		621	

622		623	
624		625	
626		627	
628		629	
630		633	
637		638	
639		641	

647		648	
649		651	
655		654	
656		658	
660		661	
662			

.

4. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

5. Use of the compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a respiratory syncytial virus infection.

6. Use of the compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a human metapneumovirus infection.